CyBio Drop automated liquid handler
Freephone: 0800 257 428 Email: sales@alphatech.co.nz
T cell receptor-engineered T cell therapy (TCR-T) and chimeric antigen receptor T cell therapy (CAR-T) are two types of adoptive T cell immunotherapy. Measurement of TCR activation using traditional methods relies on laborious protocols and highly variable end points. The TCR-alpha-beta-KO Bioassay overcomes the limitations of these existing methods and enables functional testing of transgenic TCRs for antigen ranking, specificity and safety testing for applications such as quality control, TCR-T and CAR-T therapies. The T Cell Activation Bioassay (TCR-alpha-beta-KO) is a bioluminescent cell-based assay used to measure the potency of transgenic TCR constructs to activate T cells without the constraints of endogenous TCR expression. The assay consists of a genetically engineered Jurkat T cell line with endogenous TCR alpha and beta chains knocked out using CRISPR/Cas9. These cells express a luciferase reporter driven by a TCR pathway-dependent promoter.
